A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Risankizumab (Primary) ; Methotrexate
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 15 Aug 2019 Planned End Date changed from 20 Sep 2021 to 30 Sep 2021.
- 15 Aug 2019 Planned primary completion date changed from 21 Jan 2020 to 20 Feb 2020.
- 15 Aug 2019 Status changed from recruiting to active, no longer recruiting.